What's happened
England has authorised Enhertu for routine NHS use for HER2‑low metastatic breast cancer, ensuring access for about 1,000 women annually. The decision follows a previous rejection over cost‑effectiveness and builds on a deal between NICE and drug makers AstraZeneca and Daiichi Sankyo. Scotland has already provided access since 2023.
What's behind the headline?
The Biology of Access
- The policy pivot reflects a willingness to reassess cost‑effectiveness for high‑benefit, late‑stage cancers.
- The widening of NHS access could shift budget prioritisation toward targeted oncology therapies.
- Patient advocacy groups have been pivotal in sustaining pressure after early denials.
What this means for patients
- Roughly 1,000 women per year in England may gain access to Enhertu, potentially extending life and quality of life.
- Access in other UK nations remains variable, which could lead to disparities in treatment timelines.
Risks and questions
- Will the higher price persist if demand grows or evidence evolves? How will NICE monitor value over time?
- How will Wales implement the guidance, and what about Northern Ireland's policy alignment?
How we got here
NICE previously rejected Enhertu in 2024 for cost reasons. The deal now enables England to reimburse the drug for eligible NHS patients, with Wales likely to follow and Northern Ireland not automatically covered. Scotland has had access since 2023. The drug delivers targeted chemotherapy to HER2‑low cancer cells, extending median survival in trials by several months.
Our analysis
Arab News reports NICE has cleared a key hurdle with a UK‑wide cost‑effectiveness shift; BBC News corroborates the present availability in England and notes Scotland's ongoing access; The Guardian highlights the price deal and the impact on ~1,000 women per year. Independent provides patient testimonies alongside campaigning context; BBC Business and NHS coverage discuss broader implications for care delays in cancer pathways.
Go deeper
- What will be the practical steps for a patient to access Enhertu in their area?
- How might this affect wait times for other cancer drugs on the NHS?
- What happens if NICE adjusts the price or new evidence emerges?
More on these topics
-
Northern Ireland - Country of the United Kingdom
Northern Ireland is variously described as a country, province or region which is part of the United Kingdom. Located in the northeast of the island of Ireland, Northern Ireland shares a border to the south and west with the Republic of Ireland.
-
Wales - UK constituent country
Wales is a country that is part of the United Kingdom. It is bordered by the Irish Sea to the north and west, England to the east, the Bristol Channel to the south, and the Celtic Sea to the south-west. As of 2021, it had a population of 3.2 million.
-
England - Country of the United Kingdom
England is a country that is part of the United Kingdom. It shares land borders with Wales to its west and Scotland to its north. The Irish Sea lies northwest of England and the Celtic Sea to the southwest. England is separated from continental Europe by
-
Scotland - Country of the United Kingdom
Scotland is a country that is part of the United Kingdom. Covering the northern third of the island of Great Britain, mainland Scotland has a 96 mile border with England to the southeast and is otherwise surrounded by the Atlantic Ocean to the north and w
-
AstraZeneca - Pharmaceutical company
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global headquarters in Cambridge, England. Its R&D is concentrated in Cambridge, England, Mölndal in Sweden and North America.
-
Breast Cancer Now - Charity in the UK
Breast Cancer Now is a charity in the United Kingdom which was formed in 2015 by the merger of Breast Cancer Campaign and Breakthrough Breast Cancer. It is the United Kingdom's largest breast cancer charity. Its declared "Action Plan" is "by 2050, everyon
-
Breast cancer - Cancer that originates in the mammary gland
Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include: a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. Risk factors for developing breast cancer include obesity, a lack of physical exercise, alcohol consumption, hormone replacement therapy during menopause, ionizing radiation, an early age at first menstruation, having children late in life (or not at all), older age, having a prior history of breast cancer, and a family history of breast cancer. About five to ten percent of cases are the result of an inherited genetic predisposition, including BRCA mutations among others. Breast cancer most commonly develops in cells from the lining of milk ducts and the lobules that supply these ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. There are more than 18 other sub-types of breast cancer. The diagnosis...
-
Daiichi Sankyo - Pharmaceutical company
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 2,305.4 billion in revenue in 2018.
-
National Health Service - Publicly-funded healthcare systems in the United Kingdom
The National Health Service (NHS) is the collective term for the four separate publicly funded healthcare systems of the United Kingdom: the National Health Service in England, NHS Scotland, NHS Wales, and Health and Social Care in Northern Ireland, which were created separately, and are often referred to collectively or individually as "the NHS". The three original systems for England and Wales, Scotland and Northern Ireland were established in 1948 – with a Welsh system later founded in 1969 – as part of major social reforms following the Second World War, and officially launched at Park Hospital in Davyhulme, near Manchester, England (now known as Trafford General Hospital). The founding principles were that services should be comprehensive, universal and free at the point of delivery. Each system provides a comprehensive range of health services, provided without charge for residents of the United Kingdom apart from dental treatment and optical care, though NHS patients in England who are not exempt have to pay prescription charges. Taken together, the four systems in 2015–16 employed around 1.6 million people with a combined budget of £136.7 billion. In 2024, the total health...
-
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence is an executive non-departmental public body of the Department of Health in England, which publishes guidelines in four areas:
-
British Broadcasting Corporation - Broadcasting company
The British Broadcasting Corporation is a British public service broadcaster. Headquartered at Broadcasting House in Westminster, London, it is the world's oldest national broadcaster, and the largest broadcaster in the world by number of employees.
-
West Midlands - Wikimedia disambiguation page
West Midlands may refer to: West Midlands (region), a region of the United Kingdom West Midlands (county), the metropolitan county in the West Midlands region West Midlands conurbation, the large conurbation in the West Midlands region West Midlands...
-
Royal College of Physicians, London - College in London, England
The Royal College of Physicians is a British professional body dedicated to improving the practice of medicine, chiefly through the accreditation of physicians by examination.
-
Coventry Hospital
University Hospitals Coventry and Warwickshire NHS Trust runs University Hospital Coventry and the Hospital of St. Cross situated in Rugby, Warwickshire. The trust works in partnership with the University of Warwick's Warwick Medical School.
-
Coventry - City in England
Coventry is a city, administrative centre and metropolitan borough in England and the United Kingdom. It is built on the River Sherbourne, which remains largely hidden by infrastructure, although it can be seen by the canal.
-
Temozolomide - Medication
Temozolomide, sold under the brand name Temodar among others, is a medication used to treat some brain tumors such as glioblastoma multiforme or anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.
-
Yvette Cooper - British politician
Yvette Cooper (born 20 March 1969) is a British politician who has served as Foreign Secretary since September 2025, having previously served as Home Secretary from 2024 to 2025. A member of the Labour Party, Cooper has been Member of Parliament (MP)...
-
Devon - Shire county
Devon, also known as Devonshire, is a county of England, reaching from the Bristol Channel in the north to the English Channel in the south.
-
NHS England - Non-departmental public body
NHS England is an executive non-departmental public body of the Department of Health and Social Care. It oversees the budget, planning, delivery and day-to-day operation of the commissioning side of the NHS in England as set out in the Health and Social C
-
Trastuzumab deruxtecan - Drug
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab covalently linked to the topoisomerase I inhibitor deruxtecan.